Treatment of advanced uterine sarcoma with adriamycin.
Between 1971 and 1979, 39 patients with clearly measurable metastatic or advanced recurrent sarcoma of uterine origin were treated with Adriamycin, either alone or in combination with other chemotherapeutic drugs. The median survival was 7.2 months. No patient lived beyond 32 months from the start of chemotherapy. The response rate was 10.3% (10.3% partial responses and no complete responses). The median duration of a partial response was 4 months. There was no difference between the median survival of the responders and nonresponders.
D000328:Adult; D000368:Aged; D004317:Doxorubicin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007890:Leiomyosarcoma / Q000188:drug therapy; D008875:Middle Aged; D012509:Sarcoma / Q000175:diagnosis / Q000188:drug therapy*; D014594:Uterine Neoplasms / Q000175:diagnosis / Q000188:drug therapy*
D004317:Doxorubicin